Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 65Lenalidomide 38daratumumab 35Bortezomib 32pomalidomide 31Specimen Handling 25carfilzomib 23Biopsy 23Cyclophosphamide 21Magnetic Resonance Spectroscopy 18Calcium Dobesilate 18isatuximab 14fludarabine 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11talquetamab 10iberdomide 10belantamab mafodotin 10selinexor 8Melphalan 8tocilizumab 7X-Rays 7fludarabine phosphate 6elotuzumab 6Nuclear Medicine Department, Hospital 5trametinib 4pembrolizumab 4nirogacestat 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × High-Throughput Screening Assays × 30 days × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡